NCT05379985: Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have an advanced solid tumor with KRAS p.G12A, KRAS p.G12D, KRAS p.G12R, KRAS p.G12S, or KRAS p.G12V mutations
Exclusions: Patients with tumors harboring the KRAS p.G12C mutation; Patients with known or suspected leptomeningeal or brain metastases

Comments are closed.

Up ↑